(firstQuint)A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency.

 This is a Phase 2, open label, two arm, multicenter, randomized, dose-ranging study during which adult patients with PK deficiency will receive multiple doses of AG-348 for up to 24 weeks (Core Period); eligible patients may enter an Extension Period to receive AG-348 for up to 4 additional years.

 Data will be reviewed on a regular basis and study design, dose and schedule will be adapted based on these reviews.

 The study will evaluate the safety and tolerability of multiple doses of AG-348, pharmacokinetic (PK) and pharmacodynamic (PD) profile of AG-348 and early indicators of clinical efficacy.

.

 A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency@highlight

Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 in patients with PK deficiency.

